晚期胃癌的二线治疗 课件.ppt

晚期胃癌的二线治疗;High incidence;High incidence;Highlights today;Highlights today;Overreview of first line treatment;Overreview of first line treatment;Overreview of first line treatment;Overreview of first line treatment;Overreview of first line treatment;Highlights today;Second-line treatment;Second-line treatment;Second-line treatment;1. Irinotecan has been shown to have activity in gastrointestinal cancers 2. used in a second-line setting for metastatic colon cancer, either alone or in combination with other agents (eg, fuorouracil, bevacizumab, or cetuximab);Topoisomerase I inhibitors;Topoisomerase I inhibitors;Taxanes;Taxanes;Platinum agents;Platinum agents;Platinum agents;Fluorouracil-based regimens;Fluorouracil-based regimens;S-1;Highlights today;performance status history of agents used degree of response to the first-line setting amount of metastatic disease;Predictive factors---2;Predictive factors---2;Predictive factors---2;Predictive factors---3;Highlights today;Currently no targeted agents have been approved in the treatment of advanced gastric cancer. ;Targeted therapy;Targeted therapy;Targeted therapy;Highlights today;Predictive factors;Predictive factors;Predictive factors;Conclusion The study suggests that MGC patients with good performance status and skin rash benefit most from salvage cetuximab combined with chemotherapy, even in heavily pretreated status.;Highlights today;Other endpoints;Highlights today;Take home message;Thank you！